Tanseli E Gonlugur1, Ugur Gonlugur. 1. Canakkale State Hospital, Department of Chest Diseases, Canakkale, Turkey. tefeoglu@gmail.com
Abstract
INTRODUCTION: The aims of this study were to determine the distribution of transudates and exudates among pathologically proven malignant pleural effusions, and to demonstrate the necessity for cytologic studies in patients with a transudative effusion. MATERIALS AND METHODS: This study is a retrospective review of all subjects diagnosed with malignant or paramalignant pleural effusion over a 10-year period at a tertiary hospital. The study included 67 subjects with malignant mesothelioma, 45 subjects with metastatic disease, and 36 subjects with paramalignant effusions. RESULTS: There were 55 female and 93 male subjects; the mean age of the sample was 62 years. Malignant pleural effusions were transudative in 1.5% of malignant mesotheliomas, 6.8% of metastatic diseases, and 11.1% of paramalignant effusions. CONCLUSIONS: Cytological examination of pleural fluid in patients with unexplained transudative effusion is essential to rule out malignant processes.
INTRODUCTION: The aims of this study were to determine the distribution of transudates and exudates among pathologically proven malignant pleural effusions, and to demonstrate the necessity for cytologic studies in patients with a transudative effusion. MATERIALS AND METHODS: This study is a retrospective review of all subjects diagnosed with malignant or paramalignant pleural effusion over a 10-year period at a tertiary hospital. The study included 67 subjects with malignant mesothelioma, 45 subjects with metastatic disease, and 36 subjects with paramalignant effusions. RESULTS: There were 55 female and 93 male subjects; the mean age of the sample was 62 years. Malignant pleural effusions were transudative in 1.5% of malignant mesotheliomas, 6.8% of metastatic diseases, and 11.1% of paramalignant effusions. CONCLUSIONS: Cytological examination of pleural fluid in patients with unexplained transudative effusion is essential to rule out malignant processes.
Authors: Lucía Ferreiro; Francisco Gude; María E Toubes; Adriana Lama; Juan Suárez-Antelo; Esther San-José; Francisco Javier González-Barcala; Antonio Golpe; José M Álvarez-Dobaño; Carlos Rábade; Nuria Rodríguez-Núñez; Carla Díaz-Louzao; Luis Valdés Journal: J Thorac Dis Date: 2017-01 Impact factor: 2.895
Authors: Simon Reuter; Dennis Lindgaard; Christian Laursen; Barbara Malene Fischer; Paul Frost Clementsen; Uffe Bodtger Journal: J Thorac Dis Date: 2019-04 Impact factor: 2.895